|Articles|May 1, 2018
- Pharmaceutical Executive-05-01-2018
- Volume 38
- Issue 5
Pharmaceutical Executive, May 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 8 years ago
Brands of the Year: Promise and Challengeabout 8 years ago
Gauging the Collaborative Spirit in European Healthabout 8 years ago
Gottlieb Tackles Drug Competition & Costsabout 8 years ago
Deploying the Cloud in GxP Environmentsabout 8 years ago
So Much Depends on the Physicianabout 8 years ago
Bridging Science & Strategy: An Investor’s Eyeabout 8 years ago
Patient Empowerment and the Future of Pharma Advertisingabout 8 years ago
Closing Pharma’s Digital Divideabout 8 years ago
Patient KOLs: Their Guide to Entering Crowded Marketsabout 8 years ago
The Total Care PackageAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5